INTERNATIONAL PATENT: NOEMA PHARMA AG FILES APPLICATION FOR "A TRIPLE REUPTAKE INHIBITOR FOR USE IN METHODS OF TREATING A BEHAVIORAL IMMUNO-METABOLIC CLUSTER CONDITION OR DISORDER"

GENEVA, March 9 -- NOEMA PHARMA AG (Barfusserplatz 34051 Basel) filed a patent application (PCT/EP2024/074056) for "A TRIPLE REUPTAKE INHIBITOR FOR USE IN METHODS OF TREATING A BEHAVIORAL IMMUNO-METABOLIC CLUSTER CONDITION OR DISORDER" on Aug 28, 2024. With publication no. WO/2025/045932, the details related to the patent application was published on Mar 06, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): GARIBALDI, George (Hirzbodenpark 184052 Basel)

Abstract: Disclosed herein are methods of treating or preventing a behavioral immuno-metabolic cluster (BIMC) condition or disorder in a su...